Orchestra BioMed Holdings, Inc.
NASDAQ Global MarketTotal Valuation
Orchestra BioMed Holdings, Inc. carries a market capitalization of 339.59M, placing it among publicly traded companies globally. Its enterprise value stands at 185.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 339.59M |
| Enterprise Value | 185.86M |
Share Statistics
Orchestra BioMed Holdings, Inc. currently has 60.11M shares outstanding.
| Shares Outstanding | 60.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 8.05, and the price-to-book ratio stands at 13.44.
| PE Ratio | N/A |
| PS Ratio | 8.05 |
| PB Ratio | 13.44 |
| P/TBV Ratio | 13.44 |
| P/FCF Ratio | -4.47 |
| P/OCF Ratio | -4.41 |
Enterprise Valuation
| EV / Sales | 5.81 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Orchestra BioMed Holdings, Inc. maintains a current ratio of 8.26, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.26 |
| Quick Ratio | 8.17 |
| Debt / Equity | 187.17 |
| Debt / EBITDA | -0.63 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -604.73 |
| Return on Assets (ROA) | -74.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -88.56 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.72 |
Stock Price Statistics
Orchestra BioMed Holdings, Inc.'s stock has gained approximately 44.87179% over the past 52 weeks. The 50-day moving average sits at 5.53, while the 200-day moving average is 4.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | 44.87179% |
| 50-Day Moving Average | 5.53 |
| 200-Day Moving Average | 4.48 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Orchestra BioMed Holdings, Inc. generated 31.98M in revenue and converted that into -59.03M in net income, yielding earnings per share of -0.99. EBITDA reached -57.64M, while operating income came in at -57.99M.
| Revenue | 31.98M |
| Gross Profit | 31.82M |
| Operating Income | -57.99M |
| Pretax Income | -59.03M |
| Net Income | -59.03M |
| EBITDA | -57.64M |
| EBIT | -57.99M |
| Earnings Per Share (EPS) | -0.99 |
Balance Sheet
Orchestra BioMed Holdings, Inc. holds 109.96M in cash and equivalents against 36.17M in total debt, resulting in a net debt position of 14.37M. Total book value stands at 19.32M, with working capital of 97.77M providing operational flexibility.
| Cash & Cash Equivalents | 109.96M |
| Total Debt | 36.17M |
| Net Debt | 14.37M |
| Equity (Book Value) | 19.32M |
| Book Value Per Share | 0.32 |
| Working Capital | 97.77M |
Cash Flow
Orchestra BioMed Holdings, Inc. produced -58.32M in operating cash flow over the past twelve months. After subtracting -781,000.00 in capital expenditures, free cash flow totaled -59.10M - equivalent to -0.99 per share.
| Operating Cash Flow | -58.32M |
| Capital Expenditures | -781,000.00 |
| Free Cash Flow | -59.10M |
| FCF Per Share | -0.99 |
Margins
Orchestra BioMed Holdings, Inc. operates with a gross margin of 99.51, reflecting its pricing power and cost economics. The operating margin of -181.36 and net profit margin of -184.60 provide insight into operational efficiency.
| Gross Margin | 99.51 |
| Operating Margin | -181.36 |
| Pretax Margin | -184.60 |
| Profit Margin | -184.60 |
| EBITDA Margin | -180.27 |
Dividends & Yields
The company's payout ratio of 0.49 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 0.49 |
| Shareholder Yield | -49.81 |
| FCF Yield | -22.36 |
Scores
Orchestra BioMed Holdings, Inc. posts an Altman Z-Score of -3.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.67 |